Results 51 to 60 of about 148,561 (252)
The primary objective of this study was to evaluate a novel flow cytometry-based assay of quantifying platelet phosphorylation of vasodilator-stimulated phosphoprotein (P-VASP) in cats that received clopidogrel treatment.
Ronald H. L. Li +3 more
doaj +1 more source
Hepatocellular toxicity of clopidogrel: Mechanisms and risk factors
Clopidogrel is a prodrug used widely as a platelet aggregation inhibitor. After intestinal absorption, approximately 90% is converted to inactive clopidogrel carboxylate and 10% via a two-step procedure to the active metabolite containing a mercapto ...
Lindinger, Peter W +7 more
core +1 more source
ABSTRACT Carotid free‐floating thrombus (CFFT) is a rare yet severe cause of the ischemic stroke. Early identification and appropriate management are crucial to prevent recurrent embolic events. A 76‐year‐old man experienced sudden left‐sided hemiparesis and dysarthria.
Hirofumi Matsubara +3 more
wiley +1 more source
ABSTRACT Background The residual Gensini score (rGS) was developed to quantify the severity of coronary atheroma burden after coronary revascularisation. The predictive value of the rGS for clinical outcomes in patients with ST‐segment elevation myocardial infarction (STEMI) remains unexplored.
Batric Popovic +8 more
wiley +1 more source
Effect of obesity and serum leptin level on clopidogrel resistance
Objective: Clopidogrel inhibits platelet aggregation by blockade of platelet adenosine diphosphate (ADP) P2Y12 receptor. Leptin is the obesity gene product, and its serum level increases with obesity.
Ali Dogan +5 more
doaj +1 more source
Clopidogrel is an antiplatelet drug used to reduce the risk of acute coronary syndrome and stroke. It is converted by CYP2C19 to its active metabolite; therefore, poor metabolizers (PMs) of CYP2C19 exhibit diminished antiplatelet effects.
Yun Seob Jung +4 more
doaj +1 more source
Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention
Arijit Dasgupta, Debabrata MukherjeeGill Heart Institute, University of Kentucky, Lexington, KY, USAAbstract: It is estimated that approximately a quarter of patients undergoing coronary intervention may have significant post-procedural creatinine (CK ...
Dasgupta, Arijit +3 more
core +1 more source
ABSTRACT Background Distal transradial access (dTRA) has gained attention for its lower risk of vascular complications compared to conventional transradial access (TRA). However, its feasibility and safety in patients with out‐of‐hospital cardiac arrest (OHCA) undergoing emergency percutaneous coronary intervention (PCI) remain uncertain.
Shiori Kawakami +9 more
wiley +1 more source
Antiplatelet drugs play a pivotal role in the management of patients with acute coronary syndrome. Clopidogrel is an important antiplatelet drug commonly used in the treatment of those patients. However, the variability in patient response to clopidogrel
John I. Louca +3 more
doaj +1 more source
Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction
ABSTRACT Background In patients with myocardial infarction (MI), quantifying expression of platelet FcɣRIIa (pFCG) stratifies risk of subsequent MI, stroke, and death. Aims Assess the prognostic implications of clinical risk alone and in combination with the pFCG test.
David J. Schneider +9 more
wiley +1 more source

